Aimfinity Investment Corp. I Announces Extension of the Deadline for an Initial Business Combination to March 28, 2025
Aimfinity Investment Corp. I (AIMAU) has announced an extension of its deadline to complete an initial business combination. The new deadline is now set for March 28, 2025, extended from February 28, 2025.
The extension was secured through a Monthly Extension Payment of $55,823.8 ($0.05 per Class A ordinary share) deposited into the company's trust account by I-Fa Chang, the sponsor's manager. This marks the second of nine possible monthly extensions under the company's Current Charter, which allows for extensions from January 28, 2025, to October 28, 2025.
The company, a Cayman Islands exempted special purpose acquisition company listed on Nasdaq, can continue to extend on a monthly basis until completing a business combination, subject to board determination and required payments.
Aimfinity Investment Corp. I (AIMAU) ha annunciato un'estensione della scadenza per completare una combinazione aziendale iniziale. La nuova scadenza è ora fissata per 28 marzo 2025, estesa dal 28 febbraio 2025.
L'estensione è stata garantita tramite un Pagamento Mensile di Estensione di $55,823.8 ($0.05 per azione ordinaria di Classe A) depositato nel conto fiduciario dell'azienda da I-Fa Chang, il manager dello sponsor. Questo segna la seconda delle nove possibili estensioni mensili sotto l'attuale Statuto dell'azienda, che consente estensioni dal 28 gennaio 2025 al 28 ottobre 2025.
L'azienda, una società di acquisizione a scopo speciale esentata delle Isole Cayman quotata su Nasdaq, può continuare a estendere su base mensile fino al completamento di una combinazione aziendale, soggetta alla determinazione del consiglio e ai pagamenti richiesti.
Aimfinity Investment Corp. I (AIMAU) ha anunciado una extensión de su plazo para completar una combinación empresarial inicial. La nueva fecha límite está ahora establecida para el 28 de marzo de 2025, extendida desde el 28 de febrero de 2025.
La extensión se aseguró mediante un Pago Mensual de Extensión de $55,823.8 ($0.05 por acción ordinaria de Clase A) depositado en la cuenta fiduciaria de la empresa por I-Fa Chang, el gerente del patrocinador. Esto marca la segunda de nueve posibles extensiones mensuales bajo el Estatuto Actual de la empresa, que permite extensiones desde el 28 de enero de 2025 hasta el 28 de octubre de 2025.
La empresa, una compañía de adquisición de propósito especial exenta de las Islas Caimán que cotiza en Nasdaq, puede continuar extendiendo mensualmente hasta completar una combinación empresarial, sujeta a la determinación de la junta y a los pagos requeridos.
Aimfinity Investment Corp. I (AIMAU)가 초기 사업 결합을 완료하기 위한 마감 기한을 연장한다고 발표했습니다. 새로운 마감 기한은 2025년 3월 28일로 설정되었으며, 2025년 2월 28일에서 연장되었습니다.
이번 연장은 I-Fa Chang, 후원자의 매니저에 의해 회사의 신탁 계좌에 예치된 월별 연장 지급금 $55,823.8 ($0.05 per 클래스 A 보통주)로 확보되었습니다. 이는 회사의 현재 헌장에 따라 가능한 아홉 번의 월별 연장 중 두 번째에 해당하며, 2025년 1월 28일부터 2025년 10월 28일까지의 연장을 허용합니다.
이 회사는 나스닥에 상장된 케이맨 제도 면세 특별 목적 인수 회사로, 이사회 결정 및 필요한 지급에 따라 사업 결합을 완료할 때까지 매월 연장을 계속할 수 있습니다.
Aimfinity Investment Corp. I (AIMAU) a annoncé une prolongation de son délai pour compléter une combinaison d'affaires initiale. Le nouveau délai est désormais fixé au 28 mars 2025, prolongé depuis le 28 février 2025.
Cette prolongation a été obtenue grâce à un Paiement Mensuel de Prolongation de 55 823,8 $ (0,05 $ par action ordinaire de Classe A) déposé sur le compte fiduciaire de la société par I-Fa Chang, le gestionnaire du sponsor. Cela marque la deuxième des neuf prolongations mensuelles possibles en vertu de la Charte Actuelle de la société, qui permet des prolongations du 28 janvier 2025 au 28 octobre 2025.
La société, une société d'acquisition à but spécial exonérée des Îles Caïmans cotée au Nasdaq, peut continuer à prolonger mensuellement jusqu'à la réalisation d'une combinaison d'affaires, sous réserve de la détermination du conseil et des paiements requis.
Aimfinity Investment Corp. I (AIMAU) hat eine Verlängerung der Frist für den Abschluss einer ersten Unternehmenszusammenführung angekündigt. Die neue Frist ist nun auf 28. März 2025 festgelegt, verlängert von 28. Februar 2025.
Die Verlängerung wurde durch eine Monatliche Verlängerungszahlung von $55,823.8 ($0.05 pro Stammaktie der Klasse A) gesichert, die von I-Fa Chang, dem Manager des Sponsors, auf das Treuhandkonto des Unternehmens eingezahlt wurde. Dies markiert die zweite von neun möglichen monatlichen Verlängerungen gemäß der aktuellen Satzung des Unternehmens, die Verlängerungen vom 28. Januar 2025 bis zum 28. Oktober 2025 erlaubt.
Das Unternehmen, eine von den Cayman-Inseln befreite Zweckgesellschaft, die an der Nasdaq notiert ist, kann weiterhin monatlich verlängern, bis eine Unternehmenszusammenführung abgeschlossen ist, vorbehaltlich der Entscheidung des Vorstands und der erforderlichen Zahlungen.
- None.
- None.
Wilmington, Delaware, March 06, 2025 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (the “Company” or “AIMA”) (Nasdaq: AIMAU), a special purpose acquisition company incorporated as a Cayman Islands exempted company, today announced that, in order to extend the date by which the Company mush complete its initial business combination from February 28, 2025 to March 28, 2025, on February 28, 2025, I-Fa Chang, manager of the sponsor of the Company, has deposited into its trust account (the “Trust Account”) an aggregate of
Pursuant to the Company’s fourth amended & restated memorandum and articles of association (“Current Charter”), effectively January 9, 2025, the Company may extend on a monthly basis from January 28, 2025 until October 28, 2025 or such an earlier date as may be determined by its board to complete a business combination by depositing the Monthly Extension Payment for each month into the Trust Account. This is the second of nine monthly extensions sought under the Current Charter of the Company.
About Aimfinity Investment Corp. I
Aimfinity Investment Corp. I is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company has not selected any business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with it. While the Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company, it will not complete its initial business combination with a target that is headquartered in China (including Hong Kong and Macau) or conducts a majority of its business in China (including Hong Kong and Macau).
Additional Information and Where to Find It
As previously disclosed, on October 13, 2023, the Company entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and between the Company, Docter Inc., a Delaware corporation (the “Company”), Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of Parent (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”), pursuant to which the Company is proposing to enter into a business combination with Docter involving an reincorporation merger and an acquisition merger. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. AIMA’s stockholders and other interested persons are advised to read, when available, the proxy statement/prospectus and the amendments thereto and other documents filed in connection with the proposed business combination, as these materials will contain important information about AIMA, Purchaser or Docter, and the proposed business combination. When available, the proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to stockholders of AIMA as of a record date to be established for voting on the proposed business combination. Such stockholders will also be able to obtain copies of the proxy statement/prospectus and other documents filed with the Securities and Exchange Commission (the “SEC”), without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to AIMA’s principal office at 221 W 9th St, PMB 235 Wilmington, Delaware 19801.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the pending business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of AIMA or Docter; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii): risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the prospectus filed on April 26, 2022 relating to AIMA’s initial public offering, the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2022, filed on April 17, 2023, and in the registration statement on Form F-4/proxy statement (File No. 333-284658) filed by Purchaser on January 31, 2025, as amended (the “F-4”) in connection with the proposed transactions, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and Aimfinity, Docter, and their subsidiaries undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
No Offer or Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of any potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of AIMA, Purchaser or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.
Participants in the Solicitation
AIMA, Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of AIMA’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection with the proposed business combination is set forth in the F-4.
Contact Information:
Aimfinity Investment Corp. I
I-Fa Chang
Chief Executive Officer
221 W 9th St, PMB 235
Wilmington, Delaware 19801
FAQ
What is the new deadline for Aimfinity Investment Corp. I (AIMAU) to complete its business combination?
How much did AIMAU pay for the March 2025 deadline extension?
How many more monthly extensions can AIMAU potentially request?
What are the requirements for AIMAU to extend its business combination deadline?
When did AIMAU's monthly extension option begin and when does it end?
